Clinical Trial Update: DaxibotulinumtoxinA for Blepharospasm [Phase 2]

View source ↗

Summary

Phase 2 trial update for daxibotulinumtoxinA in blepharospasm notes the study is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Blepharospasm

Drugs mentioned

• DAXXIFY (daxibotulinumtoxinA-lanm)

Snippet

Sponsor: University of Pennsylvania | Conditions: Blepharospasm of Both Eyelids, Blepharospasm of Left Eyelid | Phase 2 | Status: NOT_YET_RECRUITING